Alamar Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue grew 68% YoY, with consumables up 79% and record gross margin of 61.5%. Large UK Biobank and GSK studies, new disease panels and planned end-2027 FDA submissions support the growth and diagnostics roadmap.
-
Q3 revenue rose 68% YoY, with consumables up 79% and gross margin reaching 61.5%. FY 2026 revenue guidance increased to $121M–$123M, alongside major UK Biobank and GSK study wins.
-
The platform combines high sensitivity and multiplexing, targeting research growth and clinical diagnostics projected to reach $9B by 2035. 2026 priorities include 100 placements, higher utilization and assay expansion; FDA submission is targeted by end of 2027.
-
Q2 2026 revenue grew 82% year-over-year to $29.4 million, driven by strong consumables demand and platform adoption, with gross margin reaching 60%. Full-year revenue is projected at $116–$120 million, and the company remains well-capitalized post-IPO to support growth and R&D expansion.
-
A precision proteomics platform launched in 2024 has achieved rapid adoption, especially in neurology and Alzheimer's research, with strong revenue growth and industry-leading sales efficiency. Strategic priorities include expanding content, commercial reach, and moving toward clinical diagnostics, with FDA submission expected next year.